ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "spondyloarthritis"

  • Abstract Number: 1780 • ACR Convergence 2023

    Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study

    Jiri Baloun1, Kristyna Bubova1, Aneta Pekacova2, Lucia Ondrejcakova3, Vladimir Cervenak4, Monika Gregova5, Sarka Forejtova5, Jana Horinkova1, Jindriska Gatterova6, Michal Tomcik7, Jiri Vencovsky7, Karel Pavelka8 and Ladislav Senolt9, 1Institute of Rheumatology, Prague, Czech Republic, 2First faculty of medicine, Charles University, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Department of Medical Imaging, St Anne's University Hospital, and Faculty of Medicine, Masaryk University, Brno, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, 6Rheumatology Institute, Prague, Czech Republic, 7Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 8Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 9Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: Axial spondyloarthritis (AxSpA) is a frequent inflammatory disease with a significant impact on a patient's quality of life. Therefore, early diagnosis and recognition of…
  • Abstract Number: 2007 • ACR Convergence 2023

    Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study

    Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY

    Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
  • Abstract Number: 2209 • ACR Convergence 2023

    Prevalence and Clinical Characteristics of Late Onset Axial Spondyloarthritis: Results from a Multicentre Nationwide Study

    Margarida Lucas Rocha1, Rita Torres2, Sofia Ramiro3, Alice Morais Castro4, Alice Neves5, Ana Martins6, Ana Teodósio Chícharo1, Beatriz Mendes7, Carolina Ochôa Matos8, Catarina Soares9, Cláudia Miguel10, Cláudia Pinto Oliveira11, Hugo Parente12, J. A. Melo Gomes13, Mariana Luís14, Mariana Santos15, Maura Couto16, Miguel Bernardes17, Paula Valente18, Roberto Costa19, Sandra Sousa4, Jaime Branco20, Fernando Pimentel-Santos21 and Alexandre Sepriano22, 1Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, 2Hospital Egas Moniz, Lisboa, Portugal, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Departamento de Reumatologia, Hospital Garcia de Orta, Almada, Portugal, 5Instituto Português de Reumatologia, Lisboa, Portugal, 6Serviço de Reumatologia, Centro Hospitalar Universitário São João; Serviço de Medicina, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, 7Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 8Centro Académico de Medicina de Lisboa, Lisbon, Portugal, 9Centro Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal, 10Instituto Português de Reumatologia, Lisbon, Portugal, 11Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, 12Serviço de Reumatologia do Centro Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal, 13Clínica Reumatológica Dr. Melo Gomes, Lisboa, Portugal, 14Serviço de Reumatologia – Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 15Serviço de Reumatologia do Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz EPE, Lisboa, Portugal, 16Unidade de Reumatologia, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, 17Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, 18Serviço de Reumatologia, Centro Hospitalar Entre o Douro e o Vouga, Santa Maria da Feira, Portugal, 19Centro Hospitalar Lisboa Norte, Lisboa, Portugal, 20CHLO, EPE - Hospital Egas Moniz, Lisbon, Portugal, 21NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, 22Leiden University Medical Centre, Portela Loures, Portugal

    Background/Purpose: Axial spondyloarthritis (axSpA) typically starts before the fourth decade of life. Consistent with that, the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for…
  • Abstract Number: 2237 • ACR Convergence 2023

    Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice

    Eva Galindez-Agirregoikoa1, Diana Prieto-Peña2, Maria Luz Garcia Vivar1, Lucia Vega-Alvarez1, Cristina Vergara3, Irati Urionaguena4, Consuelo Ramos-Giráldez5, Raquel Almodovar6, Beatriz Joven Ibáñez7, Rosario Garcia-Vicuna8, Vega Jovani9, Teresa González10, Àngels Martínez-Ferrer11, Ana Urruticoechea Arana12, Bryan Josue Flores Robles13, Cristina Campos Fernández14, Lilian Maria Lopez Nunez15, Joaquin Maria Belzunegui Otano16, Marina Pavia Pascual17, Esteban Rubio18, Angel Ramos-Calvo19, Noemi Busquets20, Ana Pérez Gómez21, Francisco Miguel Ortiz Sanjuan22, Rafael Benito Melero-Gonzalez23, Cristina Macía24, María Ángeles Puche Larrubia25, Jose Antonio Pinto Tasende26, Cristina Fernandez27, Maria Paz Martinez-Vidal28, Jaime Calvo- Alén29, Emma Beltran-Catalan30, Mireia Moreno31, Silvia Pérez-Barrio32, iñigo Gorostiza Hormaeche1 and Ricardo Blanco33, 1Basurto University Hospital, Bilbao, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Infanta Sofía, Madrid, Spain, 4GALDAKAO-USANSOLO UNIVERSITY HOSPITAL, GERNIKA-LUMO, Spain, 5Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, 6Alcorcón Foundation University Hospital, Madrid, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain, 8Hospital Universitario de la Princesa, Madrid, Spain, 9Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 10Hospital General Universitario Gregorio Marañón, Madrid, Spain, 11Hospital Universitario Dr Peset Valéncia, Valéncia, Spain, 12Hospital Can Misses, Ibiza, Spain, 13Hospital Universitario San Pedro, Logroño, Spain, 14Hospital General Universitario Valencia, Valencia, Spain, 15Son llatzer, Palmanyola, Spain, 16University Hospital Donostia, Donostia-San Sebasti, Spain, 17Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 18Servicio Andaluz Salud, Sevilla, Spain, 19Complejo Hospitalario de Soria, Soria, Spain, 20HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, 21Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, 22Hospital Universitario y Politecnico La Fe, Valencia, Spain, 23CHU Vigo, O Carballino, Spain, 24Hospital Universitario Ramón y Cajal, Madrid, Spain, 25Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, 26Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 27Hospital Universitario San Juan de Alicante, Alicante, Spain, 28Hospital Universitario San Juan Alicante, Alicante, Spain, 29Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 30HOSPITAL DEL MAR, Barcelona, Spain, 31Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, 32Hospital Universitario de Basurto, Bilbao, Spain, 33Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: The EMA authorized Upadacitinib (UPA) in PsA in January 2021. UPA has shown efficacy in PsA refractory to anti-TNF in a clinical trial (RCT).…
  • Abstract Number: 0466 • ACR Convergence 2023

    Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study

    Marie Hornez1, Anna Molto2, Maxime Leroy3, beatrice banneville4, Rakiba Belkhir5, elodie chauvet6, Marion Couderc7, Emanuelle Dernis8, sandra Desouches9, Valerie Devauchelle10, Aline Frazier-Mironer11, Laure Gossec12, elisabeth Gervais13, Hubert Marotte14, Christophe Richez15, Jeremie SELLAM16, Raphaele Seror17, Véronique Le Guern18, Gaelle Guettrot-Imbert18, Nathalie Costedoat-Chalumeau19, Rene-Marc Flipo20 and Jean-Guillaume Letarouilly21, 1University of Lille, Lille, France, 2HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 3CHU Lille - Department of Biostatistics, Lille, France, 4Sorbonne universite and Pitié Salpêtrière Hospital, la Garenne Colombes, France, 5Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, 6CH Perpignan, Perpignan, France, 7CHU Gabriel Montpied, Clermont Ferrand, France, 8CH Le Mans, Le Mans, France, 9Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, 10UBO, Brest, France, 11APHP Lariboisiere Hospital, Paris, France, 12Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, 13CHU Poitiers, Poitiers, France, 14CHU Saint-Etienne, Saint-Etienne, France, 15Université de Bordeaux, Bordeaux, France, 16Sorbonne Université APHP, Paris, France, 17University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 18APHP Hôpital Cochin, Paris, France, 19Inserm DR Paris 5, Paris, France, 20La Lettre du Rhumatologue, Paris, France, 21CHU Lille, Lille, France

    Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…
  • Abstract Number: 0526 • ACR Convergence 2023

    Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies

    Maureen Dubreuil1, Karl Gaffney2, Jonathan Kay3, Victoria Navarro-Compán4, Christine de la Loge5, Alicia Ellis6, Carmen Fleurinck7, Ute Massow8, Vanessa Taieb9 and Atul Deodhar10, 1Department of Rheumatology, Boston University School of Medicine, Milton, MA, 2Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, 3Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, 4Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Raleigh, NC, 7UCB Pharma, Oosterzele, Belgium, 8UCB Pharma, Monheim am Rhein, Germany, 9UCB Pharma, Colombes, France, 10Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR

    Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
  • Abstract Number: 0844 • ACR Convergence 2023

    Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort

    Manouk de Hooge1, Rosalinde Stal2, Alexandre Sepriano3, Xenofon Baraliakos4, Monique Reijnierse5, Juergen Braun6, Désirée van der Heijde7, Floris Van Gaalen2 and Sofia Ramiro7, 1Ghent University Hospital, Hesperange, Luxembourg, 2Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, 3Leiden University Medical Centre, Portela Loures, Portugal, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5Leiden University Medical Center, Leiden, Netherlands, 6Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 7Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: To assess whether posterior element (PE) inflammation, in particular in the facet joints (FJ), is associated with new facet joint ankylosis on MRI one…
  • Abstract Number: 1395 • ACR Convergence 2023

    Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis

    Elisabet Lindqvist1, Johan Karlsson Wallman1, Jonas Sagard2, Tor Olofsson1 and Elisabeth Mogard1, 1Lund University and Skåne University Hospital, Lund, Sweden, 2Skåne University Hospital, Lund, Sweden

    Background/Purpose: Physical activity is part of the treatment of axial spondyloarthritis (axSpA), but despite this almost half of the patients do not meet the required…
  • Abstract Number: 1781 • ACR Convergence 2023

    TNF Induces Neutrophil Elastase/Gasdermin D-mediated Neutrophil Extracellular Traps in Axial Spondyloarthritis

    Yehao Li and Xiang Peng, Department of Rheumatology and Immunology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan, China

    Background/Purpose: Emerging studies have shown that neutrophil extracellular traps (NETs) are increased and associated with the disease activity in patients with axial spondyloarthritis (axSpA). However,…
  • Abstract Number: 2077 • ACR Convergence 2023

    A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis

    Elaine Bell1, Marinella Calle2 and Iain McInnes3, 1Medscape Global Education, London, United Kingdom, 2MEDSCAPE GLOBAL, London, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are challenging conditions for rheumatologists to manage. There is an increasing focus on virtual training modalities post-pandemic.…
  • Abstract Number: 2210 • ACR Convergence 2023

    Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis

    Pieter Ruytinx1, Elien Luyten1, Ann-Sophie De Craemer2, Filip Van den Bosch3, Dirk Elewaut4 and Veerle Somers1, 1Biomedical Research Institute, Hasselt University, Department of Immunology and Infection, Diepenbeek, Belgium, 2Ghent University Hospital, Gent, Belgium, 3Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 4Ghent University and VIB Center for Inflammation Research, Ghent, Belgium

    Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, an axSpA cDNA phage display library, constructed from…
  • Abstract Number: 2250 • ACR Convergence 2023

    Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies

    Dafna Gladman1, Laure Gossec2, M. Elaine Husni3, Lars Erik4, Paolo Gisondi5, Alice B. Gottlieb6, Diamant Thaçi7, Barbara Ink8, Rajan Bajracharya8, Jérémy Lambert9, Nikos Lyris8, Jason Coarse10 and William R Tillett11, 1Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 2Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, 3Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, 4Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 5Università di Verona, Verona, Italy, 6Icahn School of Medicine at Mount Sinai, New York, NY, 7Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 8UCB Pharma, Slough, United Kingdom, 9UCB Pharma, Irigny, France, 10UCB Pharma, Morrisville, NC, 11Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…
  • Abstract Number: L02 • ACR Convergence 2022

    Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

    Christopher Ritchlin1, Laura Coates2, Iain McInnes3, Philip J. Mease4, Joseph Merola5, Yoshiya Tanaka6, Akihiko Asahina7, Laure Gossec8, Alice Gottlieb9, Diamant Thaci10, Barbara Ink11, Deepak Assudani11, Rajan Bajracharya11, Vish Shende11, Jason Coarse12 and Robert Landewé13, 1University of Rochester Medical Center, Rochester, NY, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 3College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 4Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 5Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, 6University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 7Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, 8Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, 9Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 11UCB Pharma, Slough, United Kingdom, 12UCB Pharma, Raleigh, NC, 13Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
  • Abstract Number: L14 • ACR Convergence 2022

    Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

    Xenofon Baraliakos1, Atul Deodhar2, Désirée van der Heijde3, Marina Magrey4, Walter Maksymowych5, Tetsuya Tomita6, Huji Xu7, Marga Oortgiesen8, Ute Massow9, Carmen Fleurinck10, Alicia M Ellis8, Tom Vaux11, Julie Shepherd-Smith11, Alexander Marten9 and Lianne S Gensler12, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, 7Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), 8UCB Pharma, Morrisvile, NC, 9UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, 10UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 11UCB Pharma, Slough, United Kingdom, 12Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
  • Abstract Number: L15 • ACR Convergence 2022

    Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

    Xenofon Baraliakos1, Mikkel Østergaard2, Denis Poddubnyy3, Désirée van der Heijde4, Atul Deodhar5, Pedro M. Machado6, Victoria Navarro-Compán7, Kay Geert Hermann8, Mitsumasa Kishimoto9, Eun Young Lee10, Lianne S Gensler11, Uta Kiltz1, Marco Eigenmann12, Patricia Pertel13, Aimee Readie14, Hanno B. Richards12, Brian Porter15 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 6Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 7Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, 8Department of Radiology, University Hospital Charité - Campus Mitte, Charitéplatz, Berlin, Germany, 9Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 10Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 11Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 12Novartis Pharma AG, Basel, Switzerland, 13Novartis Pharma AG, Reinach, Switzerland, 14Novartis Pharmaceuticals Corporation, East Hanover, NJ, 15Novartis Pharmaceuticals Corporation, Far Hills, NJ

    Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology